London health and care reforms finally emerge to face local scrutiny

A report from thinktank the King’s Fund says the latest government plans for reorganising health and social care in England have been kept shrouded in secrecy by NHS England and taken little note of the views of the public and frontline staff. This will come as no surprise in London, where there’s been great annoyance that draft plans produced in October were not immediately opened up for general scrutiny by Londoners.

Two local authorities went ahead and published anyway. “There’s no way the NHS can produce these plans in secret,” tweeted Camden’s Labour leader Sarah Hayward when her council became the second in the country (after Birmingham’s) to unveil the 68-page draft sustainability and transformation plan (STP) for the North Central London area, which also takes in the boroughs of Barnet, Islington, Haringey and Enfield. “There is a national crisis in both the health and social care systems,” she said in a statement. “Both need to change and we recognise they could be more efficient. As the provider and commissioner of social care services in Camden, we want to be sure that future needs are reflected in this plan.”

The other borough to publish was Lib Dem-controlled Sutton, which fits into the South West London organisational “footprint” along with Croydon, Kingston, Merton, Richmond and Wandsworth. Sutton leader Ruth Dombey acknowledged some “strategic engagement” on the part of the various local NHS bodies involved and said boroughs had been informally updated on the progress of their STP. However, she said that central NHS’s not allowing the general release of its provisional version “is raising worries about its content and the process around its development”. That’s why she put the 61-page South West London draft STP out there smartish.

In all, five STP “footprints” cover Greater London out of the 44 in England as a whole. The other three are: North West London (encompassing Brent, Harrow, Hillingdon, Ealing, Hounslow, Hammersmith and Fulham, Westminster and Kensington and Chelsea); North East London (Barking and Dagenham, City of London, Hackney, Havering, Newham, Redbridge, Tower Hamlets and Waltham Forest); and South East London (Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark).

The draft STPs for the full quintet all have now been published, so at least – some will say at last – everyone can now have a look at what’s in store: see the North West one here, the North East one here and the South East one here. Passions have long been running high about these templates for reform, with some seeing them as exacting yet in some ways also potentially beneficial devolutions and integrations of vital services and others doubting they amount to anything other than mechanisms for ruthless cuts, closures and privatisations. All concerned with their creation have been feeling the strain. Now comes the anxious and heavy scrutiny.

In London, the debate has been taking place very much in the context of meeting the particular needs of a city with such a large, diverse and shifting population. The case for proper input from patients and practitioners seems exceptionally strong here. The Kings’ Fund report concludes with a summary of recommendations about the development of STP’s nationally. Several ring very true for the capital. They include:

Involvement in the STP process should be strengthened at all levels within the health and care system, particularly among clinicians, frontline staff and local authorities.

Meaningful involvement of patients and the public in the plans has not happened so far and must now be a priority.

National bodies in the NHS should ‘stress-test’ STPs to ensure that the assumptions underpinning them are credible and the changes they describe can be delivered. Realism is needed about what can be achieved within the timescales and funding available. Honesty is needed in communicating these messages to politicians and the public.

Read the report in full via here.

London health and care reforms finally emerge to face local scrutiny

Sharp Scrutiny From European Medicines Company Of Amgen And Servier Heart Drug

There could be difficulty on the horizon for ivabradine, a heart drug marketed by Servier beneath the brand names of Corlentor and Procoralan. The drug is extensively available in Europe and elsewhere, even though it is not offered in the US, exactly where it is underneath growth by Amgen. Even though it hasn’t been widely noticed– I can discover no other press reports– the European Medicines Agency explained that it has started a assessment of the drug based mostly on troubling findings from the SIGNIFY research. (Ivabradine is employed to treat sufferers with lengthy-term steady angina and extended-phrase heart failure.)

The main results of SIGNIFY are scheduled to be presented on August 31 at the European Society of Cardiology meeting in Barcelona. But on May possibly eight the European Medicines Agency announced that it had initiated a assessment of ivabradine based mostly on  preliminary benefits:

The evaluation follows preliminary final results from the SIGNIFY study, which was evaluating whether treatment method with Corlentor/Procoralan in individuals with coronary heart disease reduces the fee of cardiovascular occasions (such as heart attack) when compared with placebo (a dummy therapy). Individuals in the study received up to 10 mg twice every day, which is greater than the at the moment authorised optimum everyday dose (7.five mg twice everyday), and the final results showed a little but significant increase in the combined danger of cardiovascular death or non-fatal heart assault with the medication in a subgroup of individuals who had symptomatic angina (Canadian Cardiovascular Society class II – IV).

The European Medicines Company will now evaluate the influence of the data from the SIGNIFY study on the balance of rewards and risks of Corlentor/Procoralan and situation an opinion on whether the advertising and marketing authorisation ought to be maintained, varied, suspended or withdrawn across the EU.

Ivabradine slows the rate of the heart by inhibiting the so-called “funny” current inside of the heart’s natural pacemaker, the sinoatrial node.

It must be mentioned that Amgen recently announced that the FDA had granted rapidly track standing to the drug. But it should also be mentioned that every single FDA skilled with whom I’ve spoken has said that the fast track designation indicates definitely nothing (even though in my encounter it’s almost always a good excuse for a business to issue a press release).

Update: In a statement Amgen said that it planned to submit the FDA filing for ivabradine for individuals with chronic heart failure. The SIGNIFY trial included sufferers with continual stable coronary artery illness without having heart failure.

Sharp Scrutiny From European Medicines Company Of Amgen And Servier Heart Drug

Do plans for transforming principal care stand up to scrutiny? | Richard Vize

Ed Miliband is promising an appointment at a GP surgical treatment inside 48 hrs of in search of a consultation. Photograph: Lynne Cameron/PA Wire

The emphasis of the NHS and politicians is lastly shifting to where the transformation in healthcare demands to consider location – primary care companies. Who should commission them, how considerably income they must get and what they need to do are all being debated.

It is striking that 1 of Simon Stevens’ 1st actions as NHS England chief executive has been to tackle the paralysis in primary care improvement, by acceding to clinical commissioning group calls for a significantly greater function in establishing primary care. His invitation to CCGs to demonstrate how they would use additional powers to improve good quality and place their local NHS on a “sustainable path” is a major phase forward in turning the speak about shifting resources from hospitals to communities into action.

The shadow overall health minister, Andy Burnham, attacked the strategies simply because they open up the chance of GPs possessing a conflict of curiosity – the reason the 35,000 primary care contracts had been given to NHS England in the first place. But transparency and powerful oversight will be a key component of the exams NHS England will apply to the bids, and the contracts themselves may possibly nicely remain with its area teams, leaving the CCGs to concentrate on creating solutions and strengthening high quality. Wellness and wellbeing boards – for whom Burnham desires a a lot larger function – are the apparent selection for supplying regional oversight of CCG ideas.

This all generates a lot more governance spaghetti, but the time for organisational elegance is long past all that matters now is what performs. Offering CCGs more influence above principal care improvement is the appropriate issue to do. It speedily grew to become clear to every person – like NHS England – that location teams lack the capability, regional knowledge and major care expertise to develop and put into action ideas which would shift care from hospitals to communities.

With CCGs now in a position to range across major, community and secondary care – and signals from Stevens that they will soon have a larger part in commissioning professional providers as properly – they will now be capable to develop joined-up plans for most local services which ultimately commence to move sources.

Labour’s own massive thought for main care – unveiled on Monday – is firmly centred on electoral appeal and unburdened by information such as credible costings. Leader Ed Miliband stated that underneath Labour there would be a “same day consultation” for individuals with urgent difficulties, with all individuals entitled to a GP appointment within 48 hrs.

The party claimed it would expense £100m, to be paid for by cutting the bureaucracy developed by competitors. The outdated line that culling bureaucrats and lawyers is all which is needed to fund new providers may possibly pass muster for a press release, but it does not stand up to scrutiny.

Even if it did, the income is not adequate to increase the amount of GPs and practice nurses and adjust the way they operate – notably with greater use of technology – to safe the rapid entry for patients the get together is promising.

As the Royal University of Standard Practitioners factors out, it only amounts to about £10,000 per practice, which is going to make little inroad into the price of using additional clinicians. The RCGP claims the further value of delivering the kind of principal care services that everyone talks about is nearer £3bn, which would indicate rising the major care share of the NHS budget from 8% to eleven%. For as soon as, the college might not be exaggerating this averages at about £14m per CCG.

In the rush to broaden out-of-hospital care, basic practice should not be the unique focus for new investing. Hospital services need to be part of the out-of-hospital resolution, with their clinicians increasingly working in the community and the previous demarcations in between major, community and acute companies being taken down. It would be an terrible mistake if main care took the perspective that “it really is our turn now”. If we have discovered anything from the extreme investing on acute care, it must be that joined-up answers operate greatest.

Are you a member of our on the web local community? Join the Healthcare Specialists Network to receive normal emails and unique delivers.

Do plans for transforming principal care stand up to scrutiny? | Richard Vize

Six NHS trusts beneath fresh scrutiny in excess of higher death prices

The Colchester Hospital University NHS basis trust is currently in specific measures following Sir Bruce Keogh’s inquiry into 14 trusts with apparently higher death charges. Photograph: Nick Ansell/PA

Six hospital trusts are underneath fresh scrutiny soon after new NHS data exposed that more patients who had been taken care of there died for the duration of their keep or soon right after.

Two of the 6, Colchester Hospital University NHS foundation believe in and East Lancashire Hospitals NHS believe in, are currently in particular measures following NHS health care director Professor Sir Bruce Keogh’s inquiry final yr into 14 trusts with apparently large death charges.

Yet another of the six, Blackpool Teaching Hospitals NHS basis trust, was also between the 14 but was not amongst the eleven put into particular measures.

The NHS’s Health and Social Care Information Centre (HSCIC) on Wednesday explained that individuals three, plus Mid Cheshire Hospitals NHS basis trust, Aintree University Hospital NHS foundation trust in Liverpool and Wye Valley NHS trust in Herefordshire, all had unusually high death costs in 2012-13, as judged by the summary hospital-degree mortality indicator (SHMI).

The SHMI is one of the key approaches of measuring if a hospital trust is seeing an typical, greater or decrease than average quantity of deaths between sufferers. It is 1 of four mortality indicators used by the healthcare data experts Medical doctor Foster Intelligence to produce its influential yearly hospital guidebook.

The SHMI captures and compares the quantity of patients who die whilst getting handled as an inpatient or inside 30 days of their discharge from hospital.

The 6 have been identified to have “higher than anticipated” mortality charges beneath the SHMI.

The HSCIC explained that “the SHMI is the ratio between the real quantity of patients who die following treatment at the believe in and the amount that would be anticipated to die on the basis of regular England figures, given the qualities of the patients taken care of there”.

The centre was asked in 2010 by the Division of Overall health to produce the SHMI and publish information primarily based on it soon after considerations have been expressed that the hospital standardised mortality ratio (HMSR) was also crude and inadequate at capturing the complexity of hospital mortality rates.

The HSCIC stressed that its new SHMI information must not be taken “as a standalone verdict on a hospital trust’s overall performance”.

All round hospital death costs as judged by the SHMI appear to be improving slightly, the new data present. In between July 2012 and July 2013 a total of nine trusts had a “greater than anticipated” SHMI value, two fewer than the yr prior to, even though 17 trusts had a “reduce than expected” SMHI value, up from 16 a year earlier.

Six NHS trusts beneath fresh scrutiny in excess of higher death prices